Epsilon Energy is engaged in the acquisition, exploration, development and production of oil and natural gas reserves in the United States, Canada, the Republic of Yemen, the Federal Democratic Republic of Ethiopia and Oman.

Landec designs, develops, manufactures and sells health and wellness products for food and biomaterials markets. The company operates its business in two reportable business segments: Curation Foods, and Lifecore. The Curation Foods business is comprised of Curation Foods' packaged vegetables business sold primarily under the Eat Smart? brand, O Olive Oil & Vinegar? olive oils and wine vinegars, and Yucatan? and Cabo Fresh? guacamole and avocado food products. Lifecore is involved in the manufactures of pharmaceutical-grade sodium hyaluronate in bulk form as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of the company's proprietary PRINT? technology to transform the lives of patients. The company is focused on the development of two product candidates for which it holds commercial rights: LIQ861, which is for the treatment of pulmonary arterial hypertension, a disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death; and LIQ865, which is an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain a surgical procedure.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

StoneMor Partners is a provider of funeral and cemetery products and services in the death care industry. The company's segments include: Cemetery Operations, which include sales of cemetery interment rights, merchandise and services and the performance of cemetery maintenance and other services; and Funeral Homes Operations, which provides a range of services, including family consultation, final expense insurance products, the removal and preparation of remains, provision of caskets and related funeral merchandise, the use of funeral home facilities for visitation, worship and performance of funeral services and transportation services.